Published in Infect Immun on November 01, 2002
Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol (2003) 1.60
Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine (2009) 1.11
Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect Immun (2010) 1.00
A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun (2013) 0.98
Localized suppression of inflammation at sites of Helicobacter pylori colonization. Infect Immun (2011) 0.98
Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase. Infect Immun (2010) 0.97
HpaA is essential for Helicobacter pylori colonization in mice. Infect Immun (2006) 0.96
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther (2008) 0.92
M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens. Infect Immun (2009) 0.91
Natural killer cells and Helicobacter pylori infection: bacterial antigens and interleukin-12 act synergistically to induce gamma interferon production. Infect Immun (2005) 0.91
Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun (2004) 0.88
Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. Clin Exp Immunol (2005) 0.84
Influence of age and duration of infection on bacterial load and immune responses to Helicobacter pylori infection in a murine model. Clin Exp Immunol (2005) 0.83
Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol (2016) 0.82
Protease-activated receptor 1 suppresses Helicobacter pylori gastritis via the inhibition of macrophage cytokine secretion and interferon regulatory factor 5. Mucosal Immunol (2014) 0.82
Antibody-mediated protection against infection with Helicobacter pylori in a suckling mouse model of passive immunity. Infect Immun (2009) 0.81
Contribution of secretory antibodies to intestinal mucosal immunity against Helicobacter pylori. Infect Immun (2013) 0.77
Anti-Helicobacter pylori Properties of GutGard™. Prev Nutr Food Sci (2013) 0.75
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) 32.58
Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol (1996) 21.37
A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology (1997) 7.72
Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis (1990) 6.90
Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J Immunol (1996) 2.77
Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun (1998) 2.71
The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med (2000) 2.02
The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A (1995) 1.99
Long term serological surveillance after treatment of Helicobacter pylori infection. Gut (1991) 1.90
Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide. J Clin Microbiol (1996) 1.78
Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun (1999) 1.69
Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun (1998) 1.67
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun (1997) 1.57
Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun (2001) 1.50
Induction of B cell responses in the stomach of Helicobacter pylori- infected subjects after oral cholera vaccination. J Clin Invest (1998) 1.47
Cell-cell interactions in conjugating Escherichia coli: role of F pili and fate of mating aggregates. J Bacteriol (1978) 1.37
Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun (1997) 1.34
Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria. Gastroenterology (1997) 1.27
Helicobacter pylori and duodenal ulcer recurrence. Am J Gastroenterol (1992) 1.24
An oral B subunit: whole cell vaccine against cholera. Vaccine (1992) 1.20
Helicobacter pylori and gastric cancer: what is the real risk? Gastroenterologist (1998) 1.16
Further development of the Helicobacter pylori mouse vaccination model. Vaccine (2000) 1.15
Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect Immun (2000) 1.15
Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol Immunol (2000) 1.06
Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Vaccine (2000) 1.05
Immunity against Helicobacter pylori: significance of interleukin-4 receptor alpha chain status and gender of infected mice. Infect Immun (2001) 1.05
Quantification of conserved antigens in Helicobacter pylori during different culture conditions. Infect Immun (1997) 1.03
Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infect Immun (2002) 1.00
Human gastric B cell responses can be induced by intestinal immunisation. Gut (2001) 0.86
Local and systemic immune responses in humans against Helicobacter pylori antigens from homologous and heterologous strains. Microb Pathog (1997) 0.85
After the eradication of Helicobacter pylori infection, relapse is a serious problem in Turkey. J Clin Gastroenterol (1999) 0.82
Effect of low-dose antigen exposure on development of immunity to Helicobacter pylori infection in mice. Infect Immun (2001) 0.78
Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid. Infect Immun (1973) 6.58
Enzyme-linked immunosorbent assays for cholera serology. Infect Immun (1973) 6.10
Actions of cholera toxin and the prevention and treatment of cholera. Nature (1981) 4.78
Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids. Infect Immun (1973) 4.08
Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology (1986) 3.28
Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis (1984) 3.07
Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest (1991) 2.97
Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun (1976) 2.92
Synthesis of a precursor to the B subunit of heat-labile enterotoxin in Escherichia coli. J Bacteriol (1981) 2.84
Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis (1985) 2.78
Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol (1986) 2.77
Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun (1989) 2.74
Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay. J Clin Microbiol (1986) 2.65
The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol (1992) 2.52
Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol (1985) 2.49
Interaction of cholera toxin and toxin derivatives with lymphocytes. I. Binding properties and interference with lectin-induced cellular stimulation. J Exp Med (1974) 2.42
Development of improved cholera vaccine based on subunit toxoid. Nature (1977) 2.42
The bactericidal effect of normal human serum on E. coli strains from normals and from patients with urinary tract infections. Infection (1973) 2.39
Experimental studies on cholera immunization. II. Evidence for protective antitoxic immunity mediated by serum antibodies as well as local antibodies. Infect Immun (1972) 2.37
Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci U S A (1975) 2.18
Mechanisms of disease and immunity in cholera: a review. J Infect Dis (1977) 2.17
Intestinal antibody responses after immunisation with cholera B subunit. Lancet (1982) 2.13
Correlation between intestinal synthesis of specific immunoglobulin A and protection against experimental cholera in mice. Infect Immun (1978) 2.12
Mechanism of toxin secretion by Vibrio cholerae investigated in strains harboring plasmids that encode heat-labile enterotoxins of Escherichia coli. Proc Natl Acad Sci U S A (1984) 2.10
Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol (1991) 2.08
Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis (1983) 2.08
Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect Immun (1982) 2.08
Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun (1997) 2.05
Cross-reactivity between heat labile enterotoxins of Vibrio cholerae and Escherichia coli in neutralization tests in rabbit ileum and skin. Acta Pathol Microbiol Scand B Microbiol Immunol (1973) 2.04
Public health. The cholera crisis in Africa. Science (2009) 2.02
Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J Clin Invest (1997) 1.98
Identification of a mannose-binding pilus on Vibrio cholerae El Tor. Microb Pathog (1991) 1.94
Enterotoxin-producing bacteria and parasites in stools of Ethiopian children with diarrhoeal disease. Arch Dis Child (1976) 1.94
Fixation and inactivation of cholera toxin by GM1 ganglioside. Scand J Infect Dis (1973) 1.90
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Receptor-specific large-scale purification of cholera toxin on silica beads derivatized with lysoGM1 ganglioside. Eur J Biochem (1981) 1.89
Cloning and sequencing of Vibrio cholerae mannose-sensitive haemagglutinin pilin gene: localization of mshA within a cluster of type 4 pilin genes. Mol Microbiol (1994) 1.88
Protective antitoxic cholera immunity in mice: influence of route and number of immunizations and mode of action of protective antibodies. Acta Pathol Microbiol Scand C (1978) 1.86
Monoclonal antibodies to cholera toxin with special reference to cross-reactions with Escherichia coli heat-labile enterotoxin. Infect Immun (1983) 1.84
Conformation of protein secreted across bacterial outer membranes: a study of enterotoxin translocation from Vibrio cholerae. Proc Natl Acad Sci U S A (1987) 1.84
Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Scand J Immunol (1977) 1.83
Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun (1991) 1.82
Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization. Infect Immun (1975) 1.82
Subunit structure of cholera toxin. J Gen Microbiol (1973) 1.78
Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. Proc Natl Acad Sci U S A (1989) 1.74
Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea. Vaccine (1989) 1.73
Relative significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in colonization of infant mice by Vibrio cholerae El Tor. Infect Immun (1996) 1.70
Evaluation of a ganglioside immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin. J Clin Microbiol (1979) 1.70
Role of PCF8775 antigen and its coli surface subcomponents for colonization, disease, and protective immunogenicity of enterotoxigenic Escherichia coli in rabbits. Infect Immun (1988) 1.69
Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro. Proc Natl Acad Sci U S A (1988) 1.68
Transient entry of enterotoxin subunits into the periplasm occurs during their secretion from Vibrio cholerae. J Bacteriol (1987) 1.68
Comparative analyses of phenotypic and genotypic methods for detection of enterotoxigenic Escherichia coli toxins and colonization factors. J Clin Microbiol (2007) 1.68
Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology (1999) 1.68
Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol (2001) 1.67
Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol (1983) 1.67
Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun (1998) 1.67
Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A (1994) 1.66
Protection against cholera in breast-fed children by antibodies in breast milk. N Engl J Med (1983) 1.64
Quantitation of vibriocidal antibodies using agar plague techniques. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 1.63
Experimental studies on cholera immunization. 1. The response of neutralizing and vibriocidal antibodies in rabbits after immunization with culture filtrate material from V. cholerae. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.63
Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci (2008) 1.62
Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. Bull World Health Organ (1984) 1.62
Monoclonal antibodies to Escherichia coli heat-labile enterotoxins: neutralising activity and differentiation of human and porcine LTs and cholera toxin. Med Biol (1986) 1.61
Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. Proc Natl Acad Sci U S A (1977) 1.61
Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol (2003) 1.60
Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine (1993) 1.54
Immunodiffusion studies on Escherichia coli. 1. Identification of O, K and H antigens in an O6 strain. Acta Pathol Microbiol Scand (1969) 1.54
Induction of compartmentalized B-cell responses in human tonsils. Infect Immun (1995) 1.54
Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin. Scand J Immunol (1986) 1.52
Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine (1992) 1.49
Protective capacity of antibodies against E. coli O antigen with special reference to the avidity. Int Arch Allergy Appl Immunol (1974) 1.49
Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture. Infect Immun (1989) 1.48
Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera. Infect Immun (1994) 1.46
Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. Scand J Immunol (1987) 1.45
Oligomeric structure of cholera toxin: characteristics of the H and L subunits. J Gen Microbiol (1975) 1.44
Local antibody production in experimental pyelonephritis: amount, avidity, and immunoglobulin class. Infect Immun (1974) 1.43
Local and systemic antibody responses to naturally acquired enterotoxigenic Escherichia coli diarrhea in an endemic area. J Infect Dis (1986) 1.41
A radial diffusion agar plaque technique for estimation of the avidity of bactericidal antibodies against Vibrio cholerae. Scand J Immunol (1972) 1.41
Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1. Microb Pathog (1991) 1.41
A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A (1997) 1.40
Receptor-like glycocompounds in human milk that inhibit classical and El Tor Vibrio cholerae cell adherence (hemagglutination). Infect Immun (1983) 1.40
Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine (1996) 1.39
Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A (1996) 1.38
Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev (1999) 1.38
Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines. Biotechnology (N Y) (1993) 1.35
Reversal of cyclic AMP-mediated intestinal secretion in mice by chlorpromazine. Gastroenterology (1978) 1.32
Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immun (1995) 1.32
Protein reagent modification of cholera toxin: characterization of effects on antigenic, receptor-binding and toxic properties. J Gen Microbiol (1975) 1.32
Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J (Clin Res Ed) (1984) 1.31
Immunoglobulin and specific-antibody synthesis in vitro by enteral and nonenteral lymphoid tissues after subcutaneous cholera immunization. Infect Immun (1977) 1.31
Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun (2001) 1.31
Neutralizing antibodies against Escherichia coli and Vibrio cholerae enterotoxins in human milk from a developing country. Scand J Immunol (1976) 1.31
The maltose regulon of Vibrio cholerae affects production and secretion of virulence factors. Infect Immun (1994) 1.28
Local intravaginal vaccination of the female genital tract. Scand J Immunol (1996) 1.28
Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine (1996) 1.27
Cholera antibody production in vitro by peripheral blood lymphocytes following oral immunization of humans and mice. Clin Exp Immunol (1985) 1.27